Will a Repatha (evolocumab) generic be available in 2026?
Evolocumab (Repatha) is a biologic, so “generic Repatha” would typically mean an approved biosimilar (not a true small-molecule generic). Whether a biosimilar can launch in 2026 depends on the status of related patents and any exclusivity/settlement terms that keep competitors off the market.
DrugPatentWatch tracks patent and exclusivity information for branded drugs and is a practical place to check whether “2026” is an expected biosimilar window for evolocumab. You can look up evolocumab on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/ .
What would a biosimilar launch in 2026 require?
A biosimilar usually becomes available only after:
1) Regulatory approval by the FDA for biosimilar use, and
2) Legal/patent barriers around the reference product have expired or been cleared for commercial marketing.
For patients and payers, the most important date is the one tied to the right to market the biosimilar—not just when a particular patent expires. Patent “overhang” from related claims can delay launches even after some earlier patents lapse.
What patents typically delay evolocumab biosimilar entry?
For biologics like evolocumab, multiple patent families can cover:
- The drug substance or formulation
- Manufacturing processes
- Methods of use
- Patents held by the reference product maker and/or related assignees
Even if one patent expires, remaining patents can still restrict marketing until they expire, are invalidated, or are cleared via settlement or a successful legal challenge.
If you want the most targeted view of whether 2026 is realistic for biosimilar availability, DrugPatentWatch’s evolocumab patent map is the most relevant way to see which patents could still be blocking entry.
Is “biosimilar availability” the same as “FDA approval”?
Not always. In many cases:
- FDA approval can come first, but
- Commercial launch can be delayed by patent litigation, “skinny label” arrangements, or settlement terms that prevent sales until a later date.
So “biosimilar approved in/around 2026” does not automatically mean it will be widely available and covered at that same time.
Are there other ways evolocumab access changes before a biosimilar launches?
Yes. Even without a biosimilar launch, patients may see changes through:
- Formulary or prior authorization changes by insurers
- Price negotiations or rebates for the reference product
- Pharmacy benefit management controls that affect out-of-pocket costs
Those steps can improve access before biosimilar competition begins, but they do not replace the market effect of an approved competing biosimilar.
Where to check the specific 2026 date for evolocumab biosimilar entry
The fastest way to answer “will it be available in 2026?” with specifics is to verify the latest evolocumab patent/exclusivity status on DrugPatentWatch (including any “market entry” or “patent expiry” fields shown for that product): https://www.drugpatentwatch.com/patent/ .
If you share the country/market you mean (U.S., EU, UK, etc.), I can tailor the question to how biosimilar eligibility and patent challenges differ by region.
Sources
- DrugPatentWatch – Evolocumab/Repatha patent tracking (search starting point)